I

IGM Biosciences
D

IGMS

9.41500
USD
0.01
(0.11%)
Market Closed
Volume
3,069
EPS
-3
Div Yield
-
P/E
-3
Market Cap
559,855,264
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    F
    FATE
    -0.04500
    (-2.17%)
    2.02500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    466.72 USD
    More
News

Title: IGM Biosciences

Sector: Healthcare
Industry: Biotechnology
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.